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Abstract
Background: We recently provided evidence that HIV-1 enters HeLa-derived TZM-bl and lymphoid CEMss cells by
fusing with endosomes, whereas its fusion with the plasma membrane does not proceed beyond the lipid mixing
step. The mechanism of restriction of HIV-1 fusion at the cell surface and/or the factors that aid the virus entry
from endosomes remain unclear.
Results: We examined HIV-1 fusion with a panel of target cells lines and with primary CD4
+ T cells. Kinetic
measurements of fusion combined with time-resolved imaging of single viruses further reinforced the notion that
HIV-1 enters the cells via endocytosis and fusion with endosomes. Furthermore, we attempted to deliberately
redirect virus fusion to the plasma membrane, using two experimental strategies. First, the fusion reaction was
synchronized by pre-incubating the viruses with cells at reduced temperature to allow CD4 and coreceptors
engagement, but not the virus uptake or fusion. Subsequent shift to a physiological temperature triggered
accelerated virus uptake followed by entry from endosomes, but did not permit fusion at the cell surface. Second,
blocking HIV-1 endocytosis by a small-molecule dynamin inhibitor, dynasore, resulted in transfer of viral lipids to
the plasma membrane without any detectable release of the viral content into the cytosol. We also found that a
higher concentration of dynasore is required to block the HIV-endosome fusion compared to virus internalization.
Conclusions: Our results further support the notion that HIV-1 enters disparate cell types through fusion with
endosomes. The block of HIV-1 fusion with the plasma membrane at a post-lipid mixing stage shows that this
membrane is not conducive to fusion pore formation and/or enlargement. The ability of dynasore to interfere with
the virus-endosome fusion suggests that dynamin could be involved in two distinct steps of HIV-1 entry -
endocytosis and fusion within intracellular compartments.
Keywords: HIV fusion kinetics, hemifusion, fusion pore, dynasore, temperature-arrested intermediate, fusion inhibi-
tors, single particle tracking, beta-lactamase, intrinsic membrane curvature
Background
Infection of cells by human immunodeficiency virus type 1
(HIV-1) is a multistep process beginning with the sequen-
tial binding of the gp120 subunit of the viral envelope gly-
coprotein (Env) to CD4 and a coreceptor CCR5 or
CXCR4 [1,2]. Interactions with CD4 and coreceptor trig-
ger conformational changes in the transmembrane subunit
of Env, gp41, which ultimately mediates membrane fusion
[3,4]. As with other viruses that do not depend on low pH
for entry, HIV-1 has been widely believed to undergo
fusion at the plasma membrane, whereas endocytosis has
been regarded as a nonproductive pathway leading to
virus degradation (for example, [5-7]). This view is based
mainly on the following lines of evidence. First, HIV-1 Env
mediates cell-cell fusion at neutral pH [7,8], and the virus
itself can fuse adjacent cells expressing CD4 and corecep-
tors [9,10] (termed “fusion from without”). Second, HIV-1
infection is not compromised by mutations in the
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impair their ability to undergo ligand-mediated endocyto-
sis [5,6,11,12]. Third, in contrast to HIV-1, VSV G-pseu-
dotyped HIV particles, which constitutively enter through
endocytosis, exhibit different requirements for HIV-1
accessory proteins for infection [13], and strikingly, fail to
infect resting CD4
+ T cells [14-16]. Also, the membrane
transport activity of Arf6 (ADP-ribosylation factor 6)
appears essential for clathrin-independent CD4/HIV-1 co-
internalization and fusion, but not for fusion of VSV G
pseudotypes [17].
The above evidence, while supporting HIV-1 fusion
with the plasma membrane, are somewhat indirect and
generally do not rule out the existence of an endocytic
entry pathway for this virus. For instance, the lack of low
pH-dependence [8,18,19] simply means that HIV-1
fusion is not restricted to acidic compartments. It also
remains to be demonstrated that CD4 and coreceptor
mutants impaired in ligand-mediated endocytosis do not
co-internalize with the virus, which would allow fusion
with endosomes. On the other hand, accumulating evi-
dence support the existence of productive HIV-1 entry
through endocytosis. The observation that trans-domi-
nant negative mutants of dynamin-2 and Eps15 potently
inhibit HIV-1 fusion and infection [20] implies that this
virus relies, at least in part, on clathrin-mediated endocy-
tosis for productive entry. Moreover, a specific small-
molecule inhibitor of clathrin function interferes with
HIV-1 uptake and infectivity [21]. Finally, inhibition of
dynamin GTPase activity by dynasore effectively sup-
pressed clathrin-dependent uptake of transferrin and low
density lipoprotein [22], as well as HIV-1 endocytosis,
fusion and infectivity [23].
By employing non-invasive imaging technologies and
functional assays, we have gained further insights into
the mechanism of HIV-1 entry [23]. First, visualization of
single virus entry into cells revealed two types of fusion
events - transfer of the viral lipids into the plasma mem-
brane without the subsequent release of the viral content
(hemifusion) and release of the viral content without sig-
nificant dilution of the viral membrane marker, which
corresponds to complete virus fusion with small intracel-
lular compartments. Second, comparison of the rates of
HIV-1 escape from a membrane-impermeable fusion
inhibitor and from low temperature applied at different
times during the virus entry demonstrated a delayed pro-
tection from the temperature block compared to resis-
tance to a fusion inhibitor. Collectively, these findings
imply that HIV-1 fuses with endosomes, but fails to
undergo complete fusion with the plasma membrane. We
also found that endosomal fusion was inhibited by a
dynamin-2 inhibitor, dynasore, suggesting that dynamin
is involved both in the virus uptake and in the subse-
quent fusion step occurring within endosomes [23].
The basis for HIV’s strong preference for entry through
endosomes is not clear. Contrary to the model proposed
in [24], kinetic measurements of lipid mixing with the
plasma membrane demonstrated that the lack of com-
plete fusion at the cell surface was not due to the faster
virus uptake which would clear the virus from the plasma
membrane before it undergoes fusion. Nearly 80% of
Env- and receptor-dependent lipid mixing events at the
plasma membrane occurred before significant endocyto-
sis or endosomal fusion were detected [23,25]. Here, to
gain further insight into the determinants of HIV-1
fusion, we tested whether this virus was able to fuse with
t h ep l a s m am e m b r a n eo fd i s t i n c tt a r g e tc e l l s ,s u c ha s
lymphoid cells and U87.CD4.CCR5 cells, which appeared
to support limited fusion between immobilized viruses
and the plasma membrane of detached cells [26]. More-
over, we attempted to redirect HIV-1 fusion to the cell
surface by preventing virus uptake, using endocytosis
inhibitors or reduced temperature. However, these inter-
ventions did not favor complete fusion at the cell surface,
in spite of the extended window of opportunity to enter
from the plasma membrane. Our results thus reinforce
the notion that HIV-1 enters different cell types by endo-
cytosis and demonstrate that the failure of this virus to
f u s ew i t ht h ep l a s m am e m b r a n ei sn o td u et ot h ek i n e t i -
cally dominant endocytosis that removes fusogenic
viruses from the cell surface. Finally, we found that dyna-
sore blocked productive endocytosis of HIV-1 more effi-
ciently than virus-endosome fusion, consistent with a
more critical role of dynamin in endocytic vesicle forma-
tion compared to virus-endosome fusion.
Results
A functional approach to define the virus entry pathways
We have previously designe das t r a t e g yt od e d u c et h e
sites of entry for enveloped viruses that fuse in a low pH-
independent manner [23]. The progression of HIV-1
entry through endocytosis and fusion was analyzed by
adding either a membrane-impermeable inhibitory C-
peptide, C52L [27], or by lowering the temperature. The
HIV-1 gp41-derived C52L binds to the complementary
gp41 domain formed/exposed following the Env binding
to CD4 and coreceptors, thereby preventing the forma-
tion of the final 6-helix bundle structure [28]. Once gp41
completes folding into a stable 6-helix bundle, which
occurs immediately after, but not before the fusion pore
formation [29], fusion is no longer sensitive to C-peptide
inhibition [29-31]. Therefore, C52L targets only surface-
accessible viruses that have engaged CD4 or both CD4
and coreceptor, but have not progressed through the
fusion step (Figure 1A). Note that binding of C-peptides
to intermediate conformations of gp41 formed at the cell
surface will block subsequent HIV-1 fusion with endoso-
mal compartments. On the other hand, both cell-surface
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perature (Figure 1A).
The above approach is based on the notion that endo-
somal fusion is usually delayed relative to the virus
uptake. Thus, by comparing the rate of virus escape
from a membrane-impermeable fusion inhibitor target-
ing cell surface-bound viruses to the rate of escape from
low temperature that blocks all fusion events (referred
to as a temperature block, TB), one can deduce whether
the virus fuses at the plasma membrane or after
Figure 1 Principal HIV-1 entry pathways and a functional strategy to determine the entry site.( A )H I V - 1b i n d st oC D 4a l o n gw i t ha
coreceptor and either undergoes fusion with the plasma membrane (PM) or with an endosomal membrane (Endo). While a C-peptide only
inhibits fusion of non-internalized particles that have not fused at the time of its addition, low temperature (referred to as a temperature block,
TB) is able to inhibit both PM and Endo fusion. (B) The time course of HIV-1 escape from fusion inhibitors during entry into and fusion with
target cells. The virus sensitivity to C-peptide and TB would change at the similar rate, if fusion occurs at the plasma membrane (PM). By
contrast, viruses entering through the endosomal route would acquire resistance to C-peptide but remain sensitive to the TB until they undergo
fusion with an endosomal membrane.
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protected from the peptide inhibitor, but not from the
TB until the fusion step is completed (Figure 1A).
Therefore, identical rates of virus escape from a peptide
inhibitor and from TB (Figure 1B, solid vs. dotted line)
would be consistent with direct fusion at the plasma
membrane (PM) or with endosomal fusion immediately
following the virus uptake. By comparison, delayed
escape from the TB (Figure 1B, dashed line) implies that
fusion occurs after a considerable lag time following the
virus uptake and therefore productive entry must occur
from endosomal compartments. In this case, protection
from a peptide inhibitor likely reflects productive virus
endocytosis and not the formation of 6-helix bundles as
a result of fusion with the plasma membrane.
HIV-1 exhibits strong preference for endosomal entry into
engineered and natural target cells
Using the above functional strategy, we have previously
found that HIV-1 enters target cells via endocytosis and
fusion with endosomes [23]. Here, to test whether endocy-
tic entry of HIV-1 was cell type-dependent, we analyzed
the kinetics of HIV-1 fusion with several engineered and
natural target cells. Virus-cell fusion was examined using
the b-lactamase (BlaM) assay, which measures the transfer
of viral core-associated enzyme into the cytosol [32]. HIV-
1 cores pseudotyped with different HIV-1 envelope glyco-
proteins (Env) were bound to adherent or suspended tar-
get cells in the cold, and their fusion was initiated by
shifting to 37°C. Fusion was stopped after varied times of
incubation either by adding a fully inhibitory concentra-
tion of C52L or by chilling the samples (TB).
We have previously demonstrated that HXB2 (CXCR4-
tropic) and JRFL (CCR5-tropic) Env-pseudotyped particles
enter TZM-bl indicator cells through an endocytic path-
way, as evidenced by the delayed escape from TB com-
pared to C52L [23]. Here we asked whether the same
kinetic pattern can be observed for another CCR5-tropic
HIV-1 isolate, BaL (Figure 2A). BaL-pseudotyped particles
acquired resistance to C52L much earlier than to TB,
implying that this Env also mediates the virus uptake and
fusion with intracellular compartments. Interestingly, the
respective kinetics of HXB2 and JRFL pseudovirus escape
from the above inhibitors were close to those observed for
BaL pseudotypes (Figure 2A). These results strengthen the
argument that the tropism or the strain-specific features
of HIV-1 Env does not determine the virus entry pathway
in HeLa-derived target cells.
Next, we examined the sequence of steps leading to
HIV-1 fusion in the U87.CD4.CCR5 cells expressing
both CD4 and CCR5 [33]. Using single virus imaging,
our group has previously shown that these cells, but not
HeLa- or HOS-derived target cells, supported limited
content release form HIV-1 pseudoviruses immobilized
on coverslips [26]. Since in these experiments, target
cells were detached from the culture plates and overlaid
o ni m m o b i l i z e dv i r u s e s ,w ew a n t e dt ot e s tw h e t h e r
HIV-1 pre-bound to adherent target cells would be able
to release its content at the plasma membrane. Kinetic
experiments revealed that escape of cell-bound JRFL
viruses from the TB was markedly delayed compared to
the acquisition of resistance to C52L (Figure 2B), sug-
gesting that this virus entered the U87-derived cells pri-
marily via an endocytic pathway.
We then asked whether the kinetics of HIV-1 entry and
fusion with lymphoid cells would differ from those
observed in engineered cell lines. In agreement with our
previous results [23], HIV-1 entry into CEMss cells exhib-
ited delayed resistance to TB relative to C52L (Figure 2C).
A similar pattern was observed for PM1 cells (Figure 2D),
whereas in Jurkat cells HIV-1 escape from TB was margin-
ally delayed compared to the acquisition of resistance to
the inhibitory peptide (Figure 2E). Finally, we compared
the rates of HIV-1 escape from C52L and TB upon entry
into primary CD4
+ T cells. As can be seen from 2F, there
was modest but significant lag between the acquisition of
resistance to the inhibitory peptide and to low tempera-
ture. This result suggests that at least a fraction of fusion-
competent viruses escaped from C52L by undergoing
endocytosis and fusing with intracellular compartments.
Collectively, our findings imply that HIV-1 enters
epithelial, glial and lymphoid cells through an endocytic
route. The variable lag between the virus uptake and
fusion observed for these cells highlights the role for
cell type-dependent endosomal trafficking in delivering
HIV-1 into fusion-permissive compartments.
Single HIV-1 tracking reveals endosomal entry and fusion
with lymphoid cells
To verify HIV-1 entry through an endocytic pathway, as
suggested by the BlaM assay, we imaged the fusion of sin-
gle pseudoviruses with lymphoid cells. Co-labeling pseu-
doparticles with a small releasable viral content marker
tagged with GFP and with the lipophilic dye DiD incor-
porated into the viral envelope allowed for pinpointing
the sites of virus entry [23]. This approach takes advan-
tage of the tremendous difference in the surface area of
t h ep l a s m am e m b r a n ea n da ne n d o s o m e ,s ot h a tv i r u s
hemifusion/fusion would lead to infinite dilutions (disap-
pearance) of the lipid marker at the plasma membrane
vs. limited dilution (retention) in endosomes. The viral
content release marks the pore formation that results in
disappearance of punctate signal through dilution within
the cytosol, irrespective of the fusion site. We have pre-
viously shown that cell surface-bound HIV-1 particles
exchange lipids with the plasma membrane, but do not
release their content, an outcome suggestive of a hemifu-
sion phenotype [23,26,34]. Internalized virions, on the
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experimental approach has been validated using viruses
known to enter cells via endocytosis [23].
To further confirm that HIV-1 enters lymphoid cells
through an endocytic pathway, we tracked entry of single
JFRL Env pseudoviruses into CEM.NKR-CCR5.Luc cells
stably expressing CCR5. Virus uptake and fusion were
triggered by quickly raising the temperature in the image
field to 37°C (Figure 3A and 3C, time = 0 sec), as
described in [23]. Due to the limited cytoplasm around
the nucleus of CEM-derived cells, it was virtually impos-
sible to visualize the virus trafficking from the cell per-
iphery toward the nucleus based on spatial displacement.
Importantly, however, we were able to deduce the site of
Figure 2 Kinetics of HIV-1 fusion in engineered and natural target cells. HXB2 pseudoviruses were spinoculated at 4°C onto TZM-bl (A),
U87.CD4.CCR5 (B), CEMss (C), PM1 (D), Jurkat (E), and primary CD4
+ T cells (F). Particles pseudotyped with JRFL Env were also used in panels A
and B, and BaL pseudotypes were employed in panel A. Fusion was allowed to proceed for 90 min at 37°C in DMEM/10% FBS and measured by
the BlaM assay. Virus fusion was stopped either by adding C52L (1 μM) or by placing cells on ice (TB) after varied times of incubation. At the
end of the incubation period, cells were placed on ice, loaded with the BlaM substrate, and the extent of fusion was measured after an
overnight incubation at 12°C. Unless indicated otherwise, data points are means ± standard errors of the mean (SEM) from triplicate
measurements.
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dilution of viral lipid and content markers ([23] and see
below).
Similar to TZM-bl cells [23], two types of viral marker
redistribution events were observed with CEM-derived
cells. First, the membrane marker signal (red) quickly
dropped to the background level while the signal from
the GFP-tagged viral content (green) remained relatively
constant (Figure 3A). The lack of viral content release
concomitant with a drop of the lipid marker is suggestive
of virus hemifusion at the cell surface. Particles under-
going hemifusion usually exhibited limited movement
before and immediately after the lipid mixing step (Figure
3B). In fact, the limited displacement of these viral parti-
cles from their initial position was often caused by cell
motility associated with a steep increase in temperature
at the beginning of the experiment. The second type of
events was characterized by disappearance of the viral
content marker while the fluorescence of the membrane
dye remained virtually unchanged indicating endosomal
fusion (Figure 3C). In this case, we ordinarily observed
more extensive virus movement before the content
release events were detected (Figure 3D).
Out of the total 1238 co-labeled viral particles, 29 (2.3%)
appeared to hemifuse with the plasma membrane, while
only 7 (0.6%) underwent full fusion within endosomes
(Figure 3E). Thus, the efficiency of JRFL fusion with the
CEM-derived cell line was relatively low. As with TZM-bl
cells, JRFL fusion was primarily initiated at the cell surface,
resulting in lipid mixing but not the viral content release.
Figure 3 Imaging the HIV-1 fusion with lymphoid cells. HIV-1 JRFL Env pseudotyped MLV particles co-labeled with Gag-GFP and DiD were
bound to CEM.NKR-CCR5.Luc cells by spinoculation at 4°C. Virus uptake was triggered by raising the temperature to 37°C just prior to imaging.
(A) Hemifusion events at the cell surface were characterized by the loss of the DiD signal while the GFP-tagged viral content was retained. (B)
Hemifusion with the plasma membrane is associated with restricted particle motility. (C) Upon endosomal fusion, the membrane marker, DiD,
remained within the recipient endosome while the Gag-GFP signal was rapidly lost. (D) The virus shown in (C) underwent more extensive
movement. (E) Kinetics of the individual hemifusion (red line) or fusion (green line) events plotted as cumulative distributions as a function of
time. Arrows in A and C indicate the tracked co-labeled virus.
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ing at the plasma membrane was considerably faster than
the viral content release from endosomes (Figure 3E), con-
sistent with the delayed endocytic entry of this virus.
Importantly, the faster rate of hemifusion at the surface of
TZM-bl and CEM.NKR-CCR5.Luc cells compared to that
of the content release shows that the lack of HIV-1 fusion
with the plasma membrane was not due to a quick particle
internalization, as suggested in [24]. Clearly, HIV-1 Env
often initiates fusion with t h ep l a s m am e m b r a n ee a r l i e r
than the virus gets internalized but fails to create a func-
tional fusion pore. In summary, both the BlaM and single
virus imaging assays (Figures 2 and 3) imply that HIV-1
enters into a number of cell lines and into primary CD4
+
T cells through endocytosis.
Synchronizing HIV-1 entry through trapping the virus-
CD4-coreceptor complexes at the cell surface does not
favor fusion with the plasma membrane
We sought to optimize and accelerate the HIV-1 fusion
reaction in an attempt to redirect it from an endocytic
pathway to the plasma membrane. This was achieved by
pre-incubating the viruses with target cells at sub-
threshold temperature for fusion (18-24°C), which
resulted in creation of a temperature-arrested stage
(TAS) [23,30]. Under these conditions, a large fraction
of Env engages a requisite number of CD4 and corecep-
tors, as evidenced by resistance of fusion to high con-
centrations of CD4 [35] and coreceptor binding
inhibitors added at TAS [23,30]. Our previous studies
using a cell-cell model demonstrated that fusion from
TAS induced by raising the temperature was markedly
accelerated compared to control cells pre-incubated at
4°C [30,36]. We, therefore, reasoned that HIV-cell fusion
from this intermediate stage would also be accelerated,
thus favoring direct fusion with the plasma membrane
prior to the virus uptake.
Pseudoviruses bearing JRFL or HXB2 Env were pre-
bound to TZM-bl cells at 4°C, and TAS was created by
incubation at a temperature just below the threshold for
fusion for 2.5 h. The empirically determined optimal
temperatures for creating TAS were ~21°C for JRFL and
~24°C for HXB2. Under these conditions, only 10-20%
of fusion-competent JRFL or HXB2 particles acquired
resistance to C52L (Figure4 Aa n d4 B ,r e dc i r c l e s ) ,
apparently due to the limited virus uptake/fusion during
the extended pre-incubation at sub-threshold tempera-
ture. At the same time, 50-75% of virions became resis-
tant to CD4 and coreceptor binding inhibitors added
immediately before raising the temperature from TAS
(pink vs. yellow symbols, respectively), confirming that a
large portion of viruses had engaged both molecules.
Control samples kept for 2.5 h at 4°C exhibited minimal
or no resistance to HIV-1 entry inhibitors, consistent
with the lack of Env-CD4-coreceptor interactions or
virus uptake (black, blue and green symbols). We next
tested if the creation of TAS accelerated HIV-1 entry/
fusion, as was the case for the cell-cell fusion process
[30,36]. When fusion was initiated by shifting to 37°C,
viruses captured at TAS acquired resistance to C52L
faster than control viruses pre-incubated at 4°C (Figure
4A and 4B). This effect was more pronounced for HXB2
compared to JRFL pseudoviruses. However, as we have
previously shown [23], escape from C52L alone does not
unambiguously prove that fusion occurs at the cell sur-
face. If fusion takes place in endosomes, the virus resis-
tance to C52L would be acquired at an earlier time
through productive endocytosis (Figure 1).
In order to assess the HIV-1 entry pathway after
creating TAS, we performed comparative measurements
of the escape kinetics from C52L and TB. These mea-
surements were carried out using HXB2 particles, since
HXB2 exhibited a more pronounced acceleration of
entry from TAS (Figure 4A and 4B). As in Figure 4B,
after creating TAS, resistance to C52L was acquired fas-
ter than in control samples (Figure 4C, red vs. black cir-
cles). However, the rates of virus escape from TB were
markedly delayed relative to escape from C52L, both for
TAS-arrested and control samples (triangles vs. circles).
We thus concluded that, in spite of engaging CD4 and
coreceptors at the cell surface, the virus still failed to
fuse with the plasma membrane. Instead, the creation of
TAS appeared to accelerate productive HIV-1 endocyto-
sis, whereas fusion with endosomes (escape from TB)
occurred at the same rate as in control experiments (red
vs. black triangles). In other words, the rate of endoso-
mal fusion was virtually independent of the rate of virus
uptake.
In parallel experiments, we imaged single HXB2 pseu-
dovirus fusion with TZM-bl cells after creating TAS and
in control samples pre-incubated in the cold for 2.5
hours. However, very few fusion events (content release
from endosomes) were detected for cold pre-incubated
cells following the subsequent incubation at 37°C for 35
minutes, whereas fusion was consistently observed after
creating TAS (Figure 4D, black vs. red circles). The
shorter incubation time at 37°C and the necessity to
keep cells on ice prior to imaging (see Materials and
Methods) could contribute to the lower tolerance of sin-
gle virus fusion to pre-incubation in the cold. To aid the
assessment of the effect of TAS on the kinetics of HIV-1
fusion, we compared cells pre-incubated at 24°C to
those imaged immediately after the virus binding step
(Figure 4D, blue circles). This comparison revealed that,
in agreement with the BlaM results, the rate of single
virus fusion after TAS (proportional to the slope of
plots in Figure 4D) was virtually identical to that with-
out pre-incubation (Figure 4D, red vs. blue circles).
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about a 10 min lag, whereas fusion after TAS proceeded
without a delay. The nearly identical kinetics of fusion
measured by the BlaM assay with or without creating
TAS (Figure 4C, triangles) indicates that the BlaM activ-
ity might occur after an additional rate-limiting step,
such as a slow dilation of fusion pores between HIV-1
and endosomes. Importantly, the creation of TAS
neither eliminated the kinetic differential between C52L
and TB in BlaM experiments nor allowed single virus
fusion at the cell surface in imaging experiments.
Collectively, our data imply that synchronization of
HIV-1 fusion through formation of Env-CD4-coreceptor
complexes at the cell surface does not favor direct
fusion at that site. These conditions accelerate produc-
tive endocytosis (escape from C52L), while the rate of
fusion with endosomes (escape from TB) remains unal-
tered. The observation that after creation of TAS HIV-1
Figure 4 Synchronizing the HIV-1 fusion by pre-forming Env-CD4-coreceptor complexes does not redirect fusion to the plasma
membrane. JRFL (A) or HXB2 (B) pseudoviruses carrying BlaM-Vpr were pre-bound to TZM-bl cells in the cold and further incubated for 2.5 h at
20.5°C (JRFL), 22-24°C (HXB2) to create a temperature-arrested stage (TAS) or at 4°C (control). Fusion was induced by raising the temperature to
37°C in DMEM/10% FBS. The extent of the functional CD4 and coreceptor engagement by the virus was evaluated by adding the respective
fusion inhibitors BMS-806 (10 μM, CD4 binding), AD101 (10 μM, CCR5 binding) or AMD3100 (10 μM, CXCR4 binding) and measuring the BlaM
activity. Alternatively, the time course of HIV-1 escape from C52L (1 μM) was measured by adding the peptide at indicated time points. (C)
Similar to panel B, but, in addition to the time course of HXB2 escape from C52L, the kinetics of acquisition of resistance to the TB was also
determined. (D) HXB2 pseudotyped viruses labeled with the MLV Gag-GFP and DiD were bound to TZM-bl cells in the cold and either
immediately used for imaging experiments (blue circles) or further incubated for 2.5 h either at 4°C or, to create TAS, at 24°C. Fusion was trigged
by raising the temperature to 37°C at the onset of imaging. Single viruses were tracked and individual fusion events quantified as described in
Materials and Methods. The differences in the kinetics of the virus escape from C52L in panels B and C reflect the experimental variability due to
differences in the viral stock and the cell passage numbers.
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partments prior to undergoing fusion highlights the role
of endosome trafficking/maturation in facilitating the
virus entry.
Blocking HIV-1 uptake by a dynamin inhibitor allows lipid
mixing but not full fusion with the plasma membrane
Another strategy to redirect HIV-1 fusion to the plasma
membrane was based on preventing the virus endocyto-
sis at physiological temperature. We used the small-
molecule dynamin inhibitor, dynasore [22], which sup-
presses HIV-1 endocytosis and fusion [23]. Virions
trapped at the cell surface in the presence of this inhibi-
tor quickly lost their fusion competence, as evidenced
by the lack of recovery of the BlaM signal following the
removal of this inhibitor (supplemental material to [23]).
H o w e v e r ,w h e t h e ro rn o tH I V - 1u n d e r w e n th e m i f u s i o n
(lipid mixing) under these conditions remained unclear,
owing to the strong quenching of the viral DiD fluores-
cence by dynasore ([23], data not shown).
We further examined the nature of the dynasore-
imposed block of HIV-1 fusion. In agreement with the
previous results [23], dynasore strongly quenched the
DiD signal (Figure 5A), as well as the fluorescence of its
green analogue, DiO, and of the chemically distinct
membrane probe, R18 (Additional File 1: Figure S1A-D),
showing that the quenching effect was not specific for
the chemical structure or spectral characteristics of DiD.
In contrast to lipophilic dyes, dynasore did not alter the
signal from the viral content markers, Gag-mKO or
Gag-GFP (Additional File 1: Figure S1A-B). However,
other dynamin inhibitors, dynole 34-2 and MiTMAB,
did not affect the DiD fluorescence (Additional File 1:
Figure S1E-G). Analysis of the mean DiD fluorescence
of cell-bound viruses confirmed the loss of the red sig-
nal, while the mKO fluorescence was not significantly
affected by dynasore (Figure 5B). Importantly, we did
not detect any viral content release events at the cell
surface with or without dynasore (Figure 5).
In order to determine whether, in addition to the
direct DiD quenching by dynasore, a fraction of this sig-
nal could be lost through HXB2-cell hemifusion, ima-
ging experiments were performed in the presence of
both dynasore and a fully inhibitory concentration of
C52L. As expected, the overall fluorescence decayed
when fusion was blocked by C52L (Figure 5B), but the
diminution of the lipid dye fluorescence was less pro-
nounced than in the presence of dynasore alone. When
C52L was added during imaging, the DiD/mKO ratio
dropped by ~60% within the 40 min-incubation period,
as compared to ~85% in the absence of the peptide inhi-
bitor. The sensitivity of DiD quenching to C52L indi-
cates that a sizeable fraction of events resulting in
disappearance of DiD puncta (perhaps as much as 25%,
Figure 5B) are due to the HIV-1 Env-mediated release
of the lipid marker into the plasma membrane. This is
in contrast to rare lipid mixing events observed in the
absence of dynamin inhibitor [23].
To verify that HIV-1 can exchange lipids with the
plasma membrane in the presence of dynasore, we tracked
single HXB2 and JRFL particles. This analysis revealed two
distinct types of DiD disappearance events - fast, exhibit-
ing a nearly instantaneous drop of fluorescence (Figure
5C, D), and slow, lasting 10 min or longer (Figure 5E, F).
When experiments were performed in the presence of
both dynasore and C52L, fast events were virtually abro-
gated while the slow events remained. Figure 5G shows
the inhibition of the fast DiD decay events in the presence
of dynasore and C52L and concomitant disappearance of
already infrequent content release from endosomes. In
contrast, slow DiD decay was not noticeably affected by
the presence of C52L (data not shown). These findings are
consistent with the notion that the slow loss of DiD fluor-
escence is caused by dynasore, whereas the fast DiD decay
reflects transfer of viral lipids into the plasma membrane
mediated by Env. By definition, lipid mixing in the absence
of content release corresponds to a hemifusion phenotype.
We found that 17% of single viruses quickly released
DiD into the plasma membrane (Figure 5G), a number
that was comparable to the estimated fraction of hemi-
fusion events in the presence of C52L based on the glo-
bal image analysis (Figure 5B). In summary, through
trapping HIV-1 at the cell surface, we increased the
occurrence of Env-mediated lipid mixing. However, in
spite of the exaggerated hemifusion phenotype in the
presence of dynasore, viruses failed to undergo full
fusion with the plasma membrane.
Dynasore incorporates into lipid membranes without
significantly affecting their propensity to fuse
The DiD-quenching activity of dynasore prompted us to
investigate its effect on the stability of lipid bilayers and
their propensity to undergo hemifusion/fusion. We first
tested whether dynasore could directly inactivate the
virus. Pre-treatment of viruses with dynasore did not
significantly decrease virus-cell binding [23] or the
fusion activity (Figure 6A) compared to control viruses.
We also did not detect adverse effects of dynasore on
infectivity of immobilized viruses (data not shown).
Because dynasore did not exhibit a direct virucidal effect
on HIV-1, we concluded that the previously observed
virus inactivation by this compound [23] was dependent
on HIV-cell contact.
We then asked whether, in addition to quenching the
fluorescence of lipid dyes, dynasore can also affect the
propensity of virus and/or cell membranes to undergo
hemifusion/fusion. Toward this goal we measured the
temperature of the lamellar-inverted hexagonal (HII)
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Page 9 of 19Figure 5 HIV-1 hemifuson with the plasma membrane can be distinguished from dynasore-mediated quenching of the viral
membrane marker. (A) TZM-bl cells were pretreated with 60 μM dynasore (Santa Cruz) in HBSS
++ and centrifuged with HXB2 Gag-mKO/DiD
virus. Cells were washed with HBSS
++ and imaged in the same buffer (upper panel), in 60 μM dynasore (lower panel), or in 60 μM dynasore + 1
μM of C52L (not shown) for 30 min at 37°C. mKO is pseudocolored green and DiD is pseudocolored red. Scale bar is 20 μm. (B) The changes in
DiD intensity induced by dynasore were evaluated based on the mean fluorescence of at least 100 virions positive for both Gag-mKO and DiD.
To compensate for the focal drift and imaging artifacts related to the cell movement, the ratio of mean DiD/mKO fluorescence signals is plotted
over time. MLV Gag-mKO/DiD or Gag-GFP/DiD particles pseudotyped with HXB2 Env (C and E) or JRFL Env (D and F) were bound to TZM-bl
cells pretreated with 60 μM dynasore in HBSS
++. Individual viruses were tracked and analyzed for changes in fluorescence intensity. Single
particle tracking in the presence of dynasore demonstrated either the fast DiD decay (C andD) or slow decay (E and F) phenotypes in the
presence of dynasore. (G) The fraction of co-labeled HXB2 pseudoviruses undergoing fast lipid transfer or endosomal fusion (content release) in
control experiments or in the presence of 60 μM dynasore with or without 1 μM C52L.
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Page 10 of 19phase transition (TH) in pure lipid bilayers in the pre-
sence of dynasore and another dynamin inhibitor, MiT-
MAB. Compounds that lower the TH promote negative
membrane curvature required for the formation of a
stalk intermediate between two fusing bilayers, whereas
compounds that raise the transition temperature are
inhibitory for fusion [37-40]. To determine how modu-
lators of dynamin activity affect membrane curvature,
we studied the ability to shift the T-H of a model lipid,
dipalmitoloeoyl phosphatidylethanolamine (DiPoPE).
This lipid has a TH at about 45°C and is convenient for
these types of studies [41-43]. When dynasore was
mixed with DiPOPE, it lowered the TH of this lipid in a
dose-dependent manner (Figure 6B). However, this
effect was weak compared to known promoters of nega-
tive curvature, such as diacylglycerol [44]. In contrast,
MiTMAB, which inhibits dynamin activity by preventing
its binding to phospholipids [45], strongly increased the
TH (Figure 6B), in agreement with the previous study
[46]. Thus, MiTMAB promotes strong positive curva-
ture and is thereby expected to inhibit bilayer hemifu-
sion, whereas dynasore confers weak negative curvature
that is unlikely to be of consequence for HIV-1 fusion.
To test whether the dynasore’s modest effect on lipid
bilayers can modulate HIV-1 Env-mediated fusion, we
analyzed the kinetics of virus-cell hemifusion in the pre-
sence of this compound. The waiting times from initiat-
ing the virus fusion by raising the temperature to each
fast lipid mixing event were measured and plotted as
the number lipid mixing events over time. We found
that lipid mixing between HIV-1 and the plasma mem-
brane occurred at the same rate, irrespective of the pre-
sence of dynasore (Figure 6C). Consistent with our
previous study [23], HXB2 pseudoviruses rarely
exchanged lipids with the plasma membrane. The num-
ber of observed hemifusion events in the absence of
dynasore appears truncated, likely due to the virus clear-
ance from the cell surface through endocytosis. The
invariant kinetics of hemifusion suggests that dynasore
itself does not facilitate membrane merger, in agreement
with its weak effect on the lipid curvature (Figure 6B).
We therefore concluded that the increased number of
hemifusion events in the presence of dynasore was
caused by trapping of viruses at the cell surface and
thus extending the window of opportunity for lipid mix-
ing. Notably, the previously observed loss of HIV-1
fusion activity following a pre-incubation of cell-bound
pseudoviruses with dynasore [23] occurred over the
same time course (20 min at 37°C) as the hemifusion
events (Figure 6C). These data suggest that dead-end
hemifusion is responsible for inactivation of cell-bound
HIV-1 in the presence of dynasore.
Figure 6 The effect of dynasore on the HIV-1 fusion-
competence and on the curvature of lipid bilayers is minimal.
(A) Concentrated stocks of JRFL and HXB2 pseudoviruses (1·10
7 IU/
ml) were pretreated with 80 μM dynasore in DMEM for 20 min at
37°C. Virus inoculum was diluted 20-fold prior to adding to TZM-bl
cells and centrifuging at 4°C to aid binding. Cells were washed, and
fusion was triggered by shifting to 37°C for 90 min in DMEM/10%
FBS and measured by the BlaM assay. (B) Dynasore and MiTMAB
were mixed with DiPoPE lipid and the temperature of lamellar-HII
transition (TH) was measured by differential scanning calorimetry.
Each sample contained 5 mg of DiPoPE and varying amounts of
dynasore or MiTMAB suspended in 0.8 ml PIPES buffer (20 mM
PIPES, 1 mM EDTA, 140 mM NaCl, pH 7.4). The sample and the
same reference buffer were added to separate cells. Temperature
scans were made from 15 to 55°C at a 1°/min scan rate. The
transition temperature for each mixture was determined using a
curve fitting program DA-2 supplied by Microcal, Inc. (Northampton,
MA). This transition temperature (TH) is plotted against the mole
fraction of drug added. (C) The waiting time from triggering fusion
to HXB2 hemifusion events (fast DiD decay) with TZM-bl cells was
determined in the presence of dynasore and plotted as the number
of events over time (circles). For comparison, the kinetics of
hemifusion with the plasma membrane in the absence of dynasore
is re-plotted from [23] (triangles).
de la Vega et al. Retrovirology 2011, 8:99
http://www.retrovirology.com/content/8/1/99
Page 11 of 19Dynasore more potently blocks HIV-1 endocytosis than
subsequent fusion with endosomes
If an inhibitor can target more than one step of virus
entry, time of addition experiments would reveal the lat-
est step of this process affected by inhibitor. We have
previously reported that HIV-1 escapes from dynasore
and the TB with nearly identical kinetics, while acquiring
resistance to a peptide inhibitor at an earlier time [23].
This finding thus implies that dynasore not only blocks
HIV-1 endocytosis, but also inhibits the virus-endosome
fusion step. However, a fluorescence quenching activity
of dynasore raised concerns regarding possible off-target
effects of this compound. We therefore re-tested the
effect of dynasore from different commercial sources on
HIV-1 fusion. At 80 μM, all tested preparations effi-
ciently blocked transferrin uptake in TZM-bl cells with-
out exhibiting significant cytotoxicity (Additional File 2:
Figure S2A-G and Additional File 3: Figure S3A). At this
concentration, dynasore preparations effectively inhibited
fusion between HXB2 pseudoviruses and TZM-bl cells
(Figure 7A). By contrast, another dynamin inhibitor
dynole 34-2, when used at 80 μM, only partially inhibited
transferrin uptake (Additional File 2: Figure S2H, I) and
exhibited only a minor effect on HIV-1 fusion (Figure
7A) or endocytosis (Additional File 4: Figure S4). Since
higher concentrations of dynole 34-2 were toxic to TZM-
bl cells (Additional File 3: Figure S3B) we did not further
investigate this compound. The effect of dynasore on
HXB2 fusion with CEMss cells was also evaluated.
We found that dynasore inhibited HIV-1 fusion with
CEMss cells as effectively as with TZM-bl cells (Figure 7A,
green bars) without significantly affecting the cell viability
(data not shown). Furthermore, 80 μM of dynasore abro-
gated HXB2 fusion with primary CD4
+ T cells (Figure 7B,
filled bars). The viability of these cells was not compro-
mise by this concentration of dynamin inhibitor (Figure
7B, dark cyan bars). The potent block of HIV-1 fusion
with primary T cells by dynasore further supports the
endocytic entry route of this virus.
A considerable lag between HIV-1 escape from C52L
and the TB in TZM-bl cells (Figure 2) indicates that virus
might rely on endosomal trafficking and maturation in
order to undergo fusion. To test whether dynasore could
exert its inhibitory effect on HIV-1 fusion by interfering
with cellular trafficking, we imaged single virus movement
within target cells and applied a fully inhibitory dose of
dynasore at an arbitrary time point. The lack of noticeable
effect on virus trafficking (Additional File 5: movie 1)
argued against the possibility that dynasore could interfere
with molecular motors or cytoskeletal components
involved in virus trafficking. Using cells transfected with
GFP-Rab5, we also found that this compound did not
affect a general movement pattern of endosomes
(Additional File 6: movie S2). To conclude, we did not
detect any obvious off-target effects of dynasore in TZM-
bl cells.
To evaluate the last step of HIV-1 entry targeted by
dynasore, we compared the rates of virus escape from
C52L (receptor-mediated endocytosis), TB (fusion with
endosomes) and from dynasore added at varied times of
virus-cell incubation at 37°C. Out of five dynasore pre-
parations tested, only the Santa Cruz compound appeared
to inhibit HIV-endosome fusion step (coinciding with the
TB-sensitive step) at 80 μM, similar to dynasore previously
obtained from T. Kirchhausen (Figure 7C and [23]). For
other tested dynasore preparations, the rate of HIV-1
escape from this inhibitor tended to be closer to that for
C52L (Figure 7D, E and data not shown) than to the TB,
consistent with inhibition of receptor-mediated virus
endocytosis. However, when the concentration of different
dynasore preparations was increased to 160 μM, delayed
escape from this compound was reproducibly observed
(Figure 7D, E), suggesting that the higher dose of dynasore
targeted the HIV-endosome fusion step.
Taken together, our results showed that dynasore repro-
ducibly blocked HIV-1 endocytosis and fusion, but that
the rate of virus escape from this compound varied some-
what depending on the dynasore preparation. The remark-
able switch between inhibiting receptor-mediated
endocytosis to blocking virus-endosome fusion that
occurred in a narrow range of dynasore concentrations
could be indicative of a more stringent requirement for
dynamin to pinch off endocytic vesicles compared to its
apparent role in aiding the HIV-1 fusion with endosomes.
Interestingly, dynasore has been shown to block transfer-
rin uptake in HeLa cells at lower doses compared to those
required to inhibit HIV-1 endocytosis ([22] and Fig. 8),
perhaps suggesting the involvement of factors other than
dynamin in virus internalization.
Discussion
A large number of viruses enter host cells through intra-
cellular compartments where low pH and/or cellular pro-
teases activate the viral fusion proteins, permitting the
release of the virus’ genome from intracellular compart-
ments [23,47,48]. Studies of virus entry helped identify
new routes of endosomal trafficking. However, the entry
pathways of enveloped viruses that do not rely on low
pH to activate their fusion proteins are less well under-
stood. These viruses can enter both via direct fusion with
the plasma membrane and endocytosis. Indeed, several
viruses undergoing receptor-mediated fusion at neutral
pH appear to rely on endocytosis for productive entry
[49-51]. Studies aimed at determining the HIV-1 entry
site yielded contradicting evidence for and against the
involvement of endocytosis in productive entry of this
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Page 12 of 19Figure 7 Dynamin inhibitors from different manufacturers have similar effects on HIV-1 uptake and fusion with endosomes.H X B 2
pseudoviruses were bound to TZM-bl or CEMss cells at 4°C (see Methods), and fusion was initiated by shifting to 37°C for 90 min (in DMEM)
and measured by the BlaM assay. (A) Fusion with TZM-bl cells (black bars) in the presence or absence of 80 μM dynasore or dynole 34-2 in
DMEM. Dynasore from Ascent was used at 100 μM. The effects of DMSO (0.1% v/v) and 80 μM dynasore (Santa Cruz) on fusion with CEMss cells
are also shown (open bars). The extent of fusion in the presence of 1 μM C52L is shown for comparison. (B) Inhibition of HXB2 pseudovirus
fusion with primary CD4
+ T cells by 80 μM dynasore (Santa Cruz) and 1 μM C52L (filled bars). The effect of DMSO, dynasore and C52L on cell
viability, as determined by the MTS assay, is shown by open bars. (C-E) The kinetics of HXB2 escape from C52L, dynasore and the temperature
block (TB) applied at indicated times of incubation at 37°C. The background fusion (~15% of the maximal signal) in the presence of dynasore
was subtracted from the dynasore kinetics data to ease the comparison with the C52L and TB kinetics. Data points are means and SEM of
combined triplicate measurements from three independent experiments.
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Page 13 of 19virus [5-7,12,20,21]. The fact that HIV-1 does not rely on
low pH to infect most target cells [8,18,19] has con-
founded the identification of its entry pathways. Non-
invasive functional approaches developed by our group
[23] showed that, surprisingly, HIV-1 fusion initiated at
the cell surface was blocked at a post lipid mixing step,
whereas internalized viruses underwent complete fusion
with endosomes. However, the molecular basis for the
strong preference for entry from intracellular compart-
ments was not delineated and some evidence supporting
the HIV-1 fusion with the plasma membrane, including
the virus’ ability to fuse adjacent cells [9], remained
controversial.
In this study, we provided further evidence that HIV-1
enters distinct permissive cell lines and primary CD4
+ T
cells through endocytosis and fusion with endosomes.
This conclusion was supported by a lag between HIV-1
escape from C52L and from the TB, which was cell
type-dependent, but independent of coreceptor tropism
(Figure 2A). This lag was also not affected by attempts
to synchronize fusion by creating TAS (Figure 4C). The
cell type-dependent difference of the kinetics of virus
escape from C52L and low temperature is consistent
with the essential role of endosome trafficking and
maturation for HIV-1 entry. The HIV’s reliance on
endocytic pathways is further supported by single virus
imaging in lymphoid cells, in which we observed hemi-
fusion with the plasma membrane and complete fusion
with endosomal compartments. More importantly,
attempts to redirect HIV-1 fusion to the plasma mem-
brane, either by synchronizing the multistep fusion reac-
tion or by trapping the virus on the cell surface using
dynasore, were unsuccessful. In spite of the ability to
quench the fluorescence of lipophilic dyes, dynasore
does not strongly affect the properties of lipid bilayers
that are essential for fusion or modulate the kinetics of
hemifusion at the cell surface. It is thus unlikely that the
lack of complete fusion between HIV-1 and the plasma
membrane is due to an inadvertent effect of dynasore.
On the other hand, a short lag between HIV-1 escape
from C52L compared to escape from the TB observed
in Jurkat and in primary T cells is consistent both with
endocytic entry and with fusion at the cell surface. How-
ever, based on the single virus imaging data (Figure 3),
we propose that HIV-1 fuses with early endosomal com-
partments of lymphoid cells. The potent inhibition of
HIV-1 fusion with CEMss cells by dynasore (Figure 7A)
s u p p o r t st h i sn o t i o n .F u t u r es t u d i e so fs i n g l ev i r u s
fusion in cells exhibiting minimal kinetic differential
between the virus escape from C52L and TB in BlaM
experiments should reveal whether these cells support
HIV-1 fusion with the plasma membrane.
A recent study has demonstrated that the centrifugal
force applied to cells during spinoculation with viruses
enhances HIV-1 infection by promoting actin dynamics
[52]. Although virus spinoculation was used in our stu-
dies, actin remodeling should only promote direct fusion
at the cell surface [53]. It thus appears that HIV-1
fusion with the plasma membrane is disfavored com-
pared to fusion with endosomal compartments. We
have previously speculated that a handful of Env glyco-
proteins incorporated into a virion [54] may not be able
to promote dilation of a fusion pore formed at the cell
surface, whereas the viral content release from intracel-
lular compartments is aided by yet unknown endosomal
factor(s) [23]. Based on the late escape of HIV-1 from
inhibition by dynasore, which coincided with the escape
from the temperature block ([23] and Figure 7), it
appears that dynamin can be involved in the virus-endo-
some fusion step. In other words, this GTPase can con-
trol HIV-1 entry at two check points - receptor-
mediated uptake and fusion with endosomes. It remains
to be determined whether dynasore can also inhibit
HIV-endosome fusion in T cells.
The requirement for a somewhat higher concentration
of dynasore to block HIV-endosome fusion compared to
a dose that inhibits productive endocytosis (Figure 7D
and 7E) indicates that the fusion step may be less reliant
on dynamin activity than virus uptake. The possibility of
the dynamin involvement in HIV-endosome fusion is
not surprising, considering that this protein plays a role
in a number of cellular processes besides vesicle bud-
d i n gf r o mt h ep l a s m am e m b r a n e( r e v i e w e di n[ 5 5 ] ) .I n
particular, dynamin has been shown to regulate receptor
trafficking from late endosomes to lysosomes [56], as
well as from late endosomes to the Golgi and ER
[57-59]. Furthermore, dynasore has been reported to
block SV40 infection by inhibiting endosomal trafficking
downstream of a nocodazole-sensitive step [60]. It is
thus possible that dynamin directly or indirectly pro-
motes dilation of a fusion pore connecting the HIV-1
envelope and an endosomal membrane.
Conclusions
This study expanded and reinforced our previous find-
ing that HIV-1 enters susceptible cells by fusing with
endosomes. First, we demonstrated the existence of a
lag between HIV-1 uptake and fusion in cell lines of dif-
ferent origin and in primary CD4
+ T cells. Second, con-
sistent with HIV’s reliance on endosomal trafficking, the
progression of fusion beyond the temperature-sensitive
steps occurred at different rates in epithelial, glial and
lymphoid cells. Third, the time of addition experiments
using dynasore implied that this compound blocked
fusion of internalized viral particles. Fourth, imaging sin-
gle virus fusion with lymphoid cells identified endo-
somes as HIV-1 entry sites. Finally, in an attempt to
redirect HIV-1 fusion to the plasma membrane, we
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Page 14 of 19blocked the virus uptake. HIV-1 particles trapped on the
cell surface released a lipid marker but failed to undergo
complete fusion. Collectively, our data strongly support
the notion that HIV-1 infects cells by entering and fus-
ing with endosomes and that dynamin plays a role in
virus uptake and in the subsequent virus-endosome
fusion.
Methods
Cells and Reagents
HeLa-derived indicator TZM-bl cells expressing CD4,
CXCR4 and CCR5 (donated by Drs. J.C. Kappes and X.
Wu [61]), human T4-lymphoblastoid CEMss cells
(donated by Dr. P. Nara [62]), CEM-NKR-CCR5-Luc
cells (donated by Drs. J. Moore and C. Spenlehauer [63]),
P M - 1c e l l s( d o n a t e db yD r s .P .L u s s oa n dR .G a l l o[ 6 4 ] )
and human astroglioma U87-MG-derived U87.CD4.
CCR5 cells (donated by Dr. H. Deng and Dr. D.R. Litt-
man [33]) were obtained from the NIH AIDS Research
and Reference Reagent Program. Jurkat and human
embryonic kidney 293T/17 cells were obtained from the
ATCC (Manassas, VA). TZM-bl were grown in Dulbec-
co’s Modified Eagle Medium (DMEM, Cellgro, Manassas,
VA), whereas CEMss, CEM-NKR-CCR5-Luc, Jurkat, and
PM-1 cells were grown in RPMI-1640 (Cellgro) supple-
mented with 10% Fetal Bovine Serum (FBS, HyClone
L a b o r a t o r i e s ,L o g a n ,U T )a n d 100 U penicillin-strepto-
mycin (Gemini Bio-Products, West Sacramento, CA).
U87.CD4.CCR5 were maintained in DMEM supplemen-
ted with 15% FBS, 100U penicillin-streptomycin, 0.5 mg/
ml G418 sulfate (Cellgro), and 1 μg/ml puromycin
(Sigma, St. Louis, MO). HEK 293T/17 cells were main-
tained in DMEM supplemented with 10% FBS, 100 U
penicillin/streptomycin and 0.5 mg/ml G418 sulfate. Pri-
mary peripheral blood mononuclear cells (PBMCs) were
purified from the peripheral blood of healthy donor
(approval from Emory IRB000045690 “Phlebotomy of
Healthy Adults for Research in Infectious Diseases and
Immunology”) by Ficoll-Paque Plus (GE Healthcare, Pis-
cataway, NJ) density gradient centrifugation. CD4
+ T
lymphocytes were isolated from PBMCs by depletion of
non-CD4
+ cells (negative selection) using MACS CD4+
T Cell Isolation kit II (Miltenyi Biotec, Auburn, CA) and
MACS LD columns (Miltenyi Biotec, Auburn, CA). Puri-
fied CD4
+ T cells were cultured in RPMI medium sup-
plemented with 10% FBS, 10 ng/ml of Interleukin-2 (NIH
AIDS Reagent Program), 2.5 μg/ml of phytohemaggluti-
nin P (Sigma, St. Louis, MO) to activate the cells. Three
days after cultivation, the purified cells were used for the
assay.
The pCAGGS plasmids encoding full length or tail-
truncated JRFL or HXB2 envelope glycoproteins (Env)
were provided by Dr. J. Binley (Torrey Pines Institute,
CA) [65]. The HIV-1 based packaging vector pR8ΔEnv
lacking the env gene was from Dr. D. Trono (University
of Geneva, Switzerland). HIV-1 BaL.01 Env expression
vector (donated by Dr. J. Mascola [66]) and the pMM310
vector expressing BlaM-Vpr (donated by Dr. M. Miller
[67] were obtained from the NIH AIDS Research and
Reference Reagent Program. Vectors expressing MLV
Gag-pol, Gag-GFP, and the MLV LTR lacZ [68] were
provided by Dr. W. Mothes (Yale University).
The C52L recombinant peptide [27] was a gift from Dr.
Min Lu (Cornell University). The BMS-806 compound
[69,70] was synthesized by ChemPacific Corp. (Baltimore,
MD), AMD3100 [71] and pronase were purchased from
Sigma, and AD101 [72] was a gift from Dr. J. Strizki
(Schering Plough, Kenilworth, NJ). Dynasore was pur-
chased from Ascent Scientific LLC (Princeton, NJ), Calbio-
chem (Gibbstown, NJ), Santa Cruz Biothechnology (Santa
Cruz, CA), Sigma (St. Louis, MO) and Tocris Bioscience
(Ellisville, Missouri). Dynole 34-2 and dynole 31-2 (negaive
control for dynole 34-2) were purchased from Ascent
Scientific. DiD (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-
dicarbocyanine, 4-chlorobenzenesulfonate salt), DiO (3,3’-
dilinoleyloxacarbocyanine perchlorate) and R18 (octadecyl
rhodamine B) were purchased from Invitrogen (Carlsbad,
CA). Myristyltrimethylammonium Bromide (MiTMAB)
was obtained from Calbiochem. Hanks’ Balanced Salt
Solution with calcium and magnesium (HBSS
++) and poly-
L-lysine were from Cellgro and Sigma, respectively.
Plasmid construction
pMLV-Gag-mKO plasmid was constructed by modifying
the pMLV-Gag-YFP plasmid [73]. The mKO sequence
was amplified by PCR using KOD Xtreme DNA polymer-
ase (Novagen, Gibbstown, NJ) and the forward and the
reverse primers, 5’-TTGCGGATCCGGCGGCGGTG-
GAGCTAGCGTGAGTGTGATTAAACCAGAGATG -3’
and 5’-TTCCGCCGGCTTAGATATCGGAATGAGC-
TACTGCATCTTCTAC-3’,c o n t a i n i n gBamHI and NaeI
restriction enzyme cleavage sites, respectively. The ampli-
fied fragment was cloned into pCR4 Blunt-TOPO vector
(Invitrogen) and its sequence was verified. The YFP
sequence in the pMLV-Gag-YFP was replaced with the
mKO sequence from pCR4 Blunt-TOPO using BamHI
and NaeI restriction sites.
Virus production and characterization
To produce pseudoviruses containing the b-lactamase-Vpr
(BlaM-Vpr) a 10 cm dish of 293T/17 cells were transfected
with 2 μgp R 8 ΔEnv, 2 μg pMM310 vector expressing
BlaM-Vpr, 1 μg pcRev [74], and 3 μg pCAGGS encoding
JRFL or HXB2 or the BaL.01 expression vector, using
PolyFect Transfection reagent (Qiagen, Valencia, CA).
Fluorescently labeled pseudoviruses were produced by the
PolyFect transfection of 293T/17 cells with 2 μgM L V -
Gag-pol, 1 μg MLV-Gag-GFP or MLV-Gag-mKO, and 3
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Env provided by Dr. James Binley [65]. Twenty four hours
post-transfection, cells were labeled with either 10 μM
DiD, DiO or R18 for 4 h in the CO2 incubator at 37°C, as
described in [26], washed and incubated for an additional
24 h in fresh growth media. Forty eight hours post-trans-
fection virus-containing media was collected, passed
through 0.45 μM filters, aliquoted and stored at -80°C.
The infectious titer was determined by a b-Gal assay in
TZM-bl cells [75].
Virus-cell fusion assay
Measurements of HIV-1 fusion with target cells were car-
ried out as described previously [23]. Briefly, viruses bear-
ing the BlaM-Vpr chimera (MOI = 1) were bound to
TZM-bl cells by centrifugation at 2095 × g, 4°C for 30
min. Unbound virus was washed off and fusion was
initiated by shifting to 37°C and stopped after indicated
times either by adding the respective inhibitors or by pla-
cing cells on ice (TB). Cells were then loaded with fluores-
cent CCF4-AM substrate (Invitrogen) and incubated
overnight at 12°C. To measure HIV-1 fusion with suspen-
sion PM-1, CEMss or Jurkat cells or primary CD4
+ T cells
were harvested by centrifugation (453 × g, 5 min at 4°C)
and resuspended in HBSS
++ at 1·10
6 cells/ml. Aliquots of
1·10
5 cells/well were added to a poly-L-lysine-coated 96-
well strip plate (Corning Costar) and cells were allowed to
attach for 30 min at room temperature. Unbound cells
were removed by washing with HBSS
++,a n dt h ep l a t e s
were blocked with 100 μl/well of HBSS
++/10% FBS for 15
min at room temperature. Viruses bearing the BlaM-Vpr
were bound and the fusion was initiated as described
above. Intracellular b-lactamase activity (ratio of blue to
green fluorescence) was measured using the Synergy HT
fluorescence microplate reader (Bio-Tek, Germany).
To create the temperature-arrested stage (TAS) pseu-
doviruses (MOI = 0.8) were bound to TZM-bl cells by
spinoculation at 2095 × g for 30 min at 4°C. Unbound
virus was washed off, and the cells were incubated either
at 22-24°C (HXB2 pseudoviruses), at 18-21°C (JRFL
pseudoviruses) or at 4°C for 2.5 h. A high concentration
(10 μM) of inhibitors of CD4 binding (BMS-806), and
CXCR4 or CCR5 binding (AMD3100 and AD101,
respectively) or of gp41 6-helix-bundle formation (C52L,
1 μM) were added either immediately prior to raising
the temperature to 37°C (0 min) or after the indicated
times. At the end of the 37°C incubation, cells were
chilled and then loaded with fluorescent CCF2-AM sub-
strate (Invitrogen) and incubated overnight at 12°C.
Cell viability assay
Cytotoxic effects of dynamin inhibitors were evaluated
by the MTS assay, using CellTiter 96 Aqueous reagent
(Promega) according to the manufacturer’s
specifications. Briefly, 1·10
5 cells per well in a 96-well
plate were treated with 50 μl DMEM containing speci-
fied compounds for 90 min at 37°C, after which time,
DMEM was replaced with 50 μl DMEM/10% FBS con-
taining 10 μl of CellTiter 96 Aqueous reagent. The cells
were further incubated for additional 2 h at 37°C. The
resulting absorbance from wells was recorded at 490
nm, using a plate reader.
Diferential scanning calorimetry
Dynasore (Santa Cruz Biotechnology) was dissolved in a
mixture of chloroform:methanol 2:1 to make a 1 mg/ml
solution. A preparation of a dynasore monohydrate sup-
plied by Sigma was found to have poorer solubility in non-
polar solvents and showed somewhat poorer mixing with
DiPoPE. Only the results from the Santa Cruz preparation
are reported here. The dynamin inhibitor, MiTMAB, was
dissolved in methanol so as to make a 1 mg/ml solution.
Aliquots of these solutions were added to a set of tubes
each containing 5 mg DiPoPE in chloroform:methanol 2:1,
to end up with mole fractions of drug ranging from 0 to
~0.05. The solvent was evaporated under a stream of
nitrogen gas so as to make thin films on the walls of the
glass tubes. The tubes were further dried for three hours
in a vacuum desiccator and kept under argon gas at -20°C
until use. For calorimetry, the films were suspended in 0.8
ml PIPES buffer (20 mM PIPES, 1 mM EDTA, 140 mM
NaCl, pH 7.4) with vigorous vortexing, degassed and
added to the calorimeter cell at room temperature, with
pure buffer in the reference cell. Temperature scans were
made from 15 to 55°C at a 1°/min scan rate. The transition
temperature for the liquid crystalline to the inverted hexa-
gonal phase of DiPoPE is ~45°C. The transition tempera-
ture for each mixture was determined from a heating scan
using a curve fitting program DA-2 supplied by Microcal,
Inc. (Northampton, MA).
Single virus imaging and image analysis
Fluorescence changes caused by dynasore and other com-
pounds were monitored by adhering double-labeled viruses
(~ 0.5·10
5 infectious units) for 30 min at 4°C to 8-well
chamber slides (Lab-Tek) pre-coated with 0.1 mg/ml poly-
L-lysine. Images were acquired every 10 sec for 10 min at
room temperature, using the Personal DeltaVision imaging
system (Applied Precision LLC., Issaquah, WA). Two con-
secutive images were acquired at each time point, by alter-
nating the standard FITC, TRITC or CY5 excitation/
emission filters, depending on the fluorescent probes used.
Green and orange/red signals were separated by a quad
(DAPI/FITC/TRITC/Cy5) dichroic beam-splitter and
sequentially acquired using an EM-CCD camera
(Photometrics).
For imaging HIV pseudovirus fusion, cells were grown
overnight on 35mm Lab-Tek glass bottom dishes to
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washed once with HBSS
++, and pseudoviruses (MOI ~
0.2) were spinoculated onto cells at 2095 × g for 30 min
at 4°C. Free virus was removed by washing with cold
HBSS
++, cells were covered with 100 μlo fc o l dH B S S
++
and transferred into an environmental enclosure main-
tained at 37°C. Once a suitable image field was found
(within 1 min after transferring into the enclosure), 1 ml
of pre-warmed HBSS
++ was added to the plate to initiate
virus uptake and fusion, and image acquisition started.
Images were acquired using the Personal DeltaVision
imaging system using a UPlanFluo 40x/1.3NA oil-
immersion objective (Olympus). Two consecutive
images with 3 Z-sections 2.5 μm apart were acquired
every 10 sec for 40 min by alternating the standard exci-
tation/emission filters as listed above.
For confocal imaging of virus fusion, CEM.NKR-
CCR5.Luc cells were attached to No. 0 glass coverslips
coated with poly-L-lysine by a brief (20 min) centrifuga-
tion at 12°C, 600 × g, as described in [23]. Loosely
bound cells were removed by washing, and coverslips
were further centrifuged with the pseudovirus inoculum
for 40 min at 12°C, 1000 × g. Cells were washed again
and kept on ice for no longer than 3 h prior to imaging.
Pieces of coverslip were then transferred into a custom-
made glass-bottom imaging chamber, and virus fusion
was initiated by raising the temperature locally to 37°C,
using a custom-built temperature-jump setup [29].
Images were acquired with the C-Apo 40×/1.2NA water
immersion objective, using the Zeiss LSM510Meta con-
focal microscope. Fluorescence signals from Gag-GFP
and DiD labeled viruses were separated using a standard
filter set. Three Z-sections separated by 3.0 μmw e r e
a c q u i r e da te a c ht i m ep o i n tw i t ht h ep i n h o l es e tt o3 4 0
μm.
The HIV-1 pseudovirus fusion with TZM-bl cells was
imaged as described previously [23], except that viruses
were bound to cells by spinoculation at 4°C and addi-
tionally incubated for 2.5 h at 24°C to create TAS (or at
4°C in control experiments). Cells were kept on ice for
up to 3 h and used for visualizing HIV-1 entry and
fusion by confocal microscopy, as detailed above.
Additional material
Additional file 1: Figure S1. Dynasore, but not dynole or MiTMAB,
quenches the fluorescence of lipophilic dyes. (A) HXB2 pseudotyped
viruses co-labeled with Gag-mKO/DiD (upper panel) or Gag-mKO/DiO
(lower panel, DiO is colored red) were adhered to poly-L-lysine coated
coverslips. Sixty μM of dynasore (Santa Cruz) in HBSS
++ was added 1 min
after beginning the image acquisition. Scale bar is 20 μm. (B) Mean
fluorescence from co-labeled viruses (at least 100 particles per image
field) was calculated and plotted over time. Dashed line shows the
change in the DiD signal in another experiment when the compound
was removed by washing. (C) HXB2 pseudoviruses co-labeled with Gag-
GFP and R18 (C, D) or DiD (E-G) were adhered to poly-lysine coated
chambered coverslips and imaged in HBSS
++ for 5 min at room
temperature. Sixty μM of dynasore (C, D), 80 μM of MiTMAB (E, F) or 60
μM of dynole 34-2 (G) in HBSS
++ was added at the 1 min point (arrows).
At least 100 co-labeled viruses were analyzed for changes in the mean
fluorescence intensity of GFP, mKO, DiD and R18 over time.
Additional file 2: Figure S2. Transferrin uptake is blocked by
dynasore and partially inhibited by dynole. TZM-bl cells were left
untreated (A, B) or were pretreated with 80 μM dynasore from different
manufacturers (C-G), dynole 34-2 (H) or with dynole 31-2 (inactive
control, I) dissolved in DMEM for 30 min at 4°C or 37°C. Cells were then
incubated with 20 μg/ml of transferrin-Alexa488 (Invitrogen) in the cold,
washed and further incubated for 10 min at 4°C (black histogram) or at
37°C (red line) in the absence or in the presence of dynamin inhibitors.
Residual transferrin-Alexa488 at the cell surface was removed by pronase
treatment (2 mg/ml, 10 min on ice), cells were washed with cold PBS
supplemented with 10% FBS and resuspended in an appropriate volume
of cold PBS. Transferring uptake was measured by flow cytometry (FACS
LSRII, BD Biosciences) gating on live cells negative for the propidium
iodide staining.
Additional file 3: Figure S3. Dynole, but not dynasore, affects the
cell viability at concentrations that inhibit transferrin endocytosis.
(A) The dose-dependent effect of dynasore from different manufacturers
on TZM-bl cell viability was as determined by the MTS assay, using
CellTiter 96 Aqueous reagent (Promega) according to the manufacturer’s
specifications. The resulting absorbance measured at 490 nm in triplicate
wells was normalized to the signal from untreated cells. Error bars are
SEM. (B) The effect of dynole 34-2 and dynole 31-2 (inactive compound)
from Ascent on TZM-bl cell viability determined by the MTS assay.
Additional file 4: Figure S4. The effect of dynole on the uptake of
HIV-1 pseudoviruses. Representative images of HXB2 pseudovirus
uptake by TZM-bl cells are shown. Cells were pretreated with 60 μM
dynole 34-2 (A) or with 60 μM dynole 31-2 (inactive compound) (B) in
HBSS
++ for 30 min followed by binding of pseudoviruses co-labeled with
HIV Gag-Cherry and EcpH-ICAM-1 (a chimera consisting of the Ecliptic
pHluorin and the ICAM-1 transmembrane domain [23,25]). Cells were
washed to remove unbound viruses and either imaged immediately (0
min) or incubated for 60 min at 37°C (60 min) in the presence of a
dynamin inhibitor, using the Zeiss LSM780 confocal microscope. Scale
bar is 20 μm. (C) Quantification of pseudovirus uptake exemplified in
panels A and B. Z-stacks of cells from at least 5 random areas were
acquired. Virus entry into acidic endosomes upon incubation at 37°C was
manifested by quenching of the EcpH fluorescence (green) while the
signal from mCherry-tagged viral cores (red) was not significantly altered.
The total EcpH intensity from several hundreds of cell-associated double-
labeled viruses was determined, and the ratio of the sum of EcpH signal
to the sum of mCherry signal (normalized to that at time = 0) was
plotted.
Additional file 5: Movie 1. Dynasore does not affect HXB2 virus
motility. HXB2 pseudoviruses co-labeled with Gag-mKO (green) and DiD
(red) were bound to TZM-bl cells at 4°C, and cells were transferred to 37°
C to initiate fusion, at which point the and imaging begun. After 5 min,
60 μM dynasore (Santa Cruz) was added to cells, and acquisition
continued for an additional 15 min. Images were acquired using the
Personal DeltaVision system.
Additional file 6: Movie 2. Rab5 motility is not altered by dynasore
treatment. TZM-bl cells were transfected with Rab5-GFP. Twenty four
hours after transfection, cells were imaged at 37°C. After 5 min, 60 μMo f
dynasore (Santa Cruz) was introduced and imaging was continued for
additional 15 min. Images were acquired using the Personal DeltaVision
system and processed with the Spot Enhancing Filter 2D plugin from
ImageJ.
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